What If You Could Skip the Factory and Build CAR-T Cells Inside the Patient?
Create Medicines just raised $122M to build CAR-T cells directly inside patients' bodies, no blood collection or factory required. With 50-plus patients already dosed, the company claims the largest clinical dataset in in vivo CAR-T, and some of biotech's sharpest investors are doubling down.
$122 Million Says You Can
Traditional CAR-T therapy is one of the most powerful cancer treatments ever invented. It's also one of the most annoying to manufacture.
Doctors pull a patient's blood through a process called leukapheresis, ship the cells to a specialized facility, spend weeks genetically engineering them into cancer-killing machines, then ship them back and infuse them. It's like ordering a custom suit, except the tailor is in another state, you're running out of time, and if anything goes wrong during fitting, you start over.
Create Medicines just raised $122 million in a Series B round to bet that none of that is necessary. The Cambridge-based biotech thinks it can build CAR-T cells directly inside a patient's body, no factory required. And based on who's writing the checks, the smart money agrees.
The "Just Add Water" Approach to Cell Therapy
Create's platform works like a biological software update delivered wirelessly. Instead of extracting T cells and reprogramming them in a lab, the company packages instructions (in the form of mRNA) inside tiny fat bubbles called lipid nanoparticles, or LNPs. If that delivery system sounds familiar, it should: LNPs are the same technology that made the COVID mRNA vaccines work.
Once injected, these nanoparticles find T cells circulating in the bloodstream. The T cells absorb them, read the mRNA instructions, and start building CAR proteins on their surface. Those CARs act like targeting systems, locking onto specific markers on cancer cells or rogue immune cells. Within hours, the patient's own immune system has been reprogrammed without ever leaving their body.
The elegance here is in what you don't need: no leukapheresis machines, no clean rooms, no weeks of manufacturing, no cross-country shipping of frozen cells. It's the difference between downloading a movie and waiting for a Blu-ray in the mail.
50 Patients and Counting
Create isn't just pitching a cool idea on a whiteboard. The company says it has dosed more than 50 patients across its in vivo CAR-T clinical programs, which it claims is the . That's a meaningful head start.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
largest clinical dataset in the entire in vivo CAR-T field
For context, many competitors in the in vivo CAR-T space are still in preclinical stages or have treated only a handful of patients. EsoBiotec, which AstraZeneca scooped up, published data on just four patients in its initial cohort. Create's 50-plus patients represent a real, if early, body of evidence that this approach can work in humans.
The company hasn't released detailed efficacy or safety data from these patients publicly (at least not in the materials available). But having that many people dosed gives Create something invaluable: experience. In drug development, knowing what happens in real patients is the only currency that truly matters.
Where the Money Goes
The $122 million round was co-led by three existing investors: Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners. Alexandria Venture Investments also participated, along with other members of Create's existing syndicate.
These aren't casual backers. ARCH Venture Partners recently closed a roughly $3 billion fund dedicated to early-stage biotech, and its portfolio reads like a greatest-hits album of the industry (Illumina, Alnylam, Juno Therapeutics). Newpath Partners focuses exclusively on life sciences "company creation" and has backed other cutting-edge platform plays like Prime Medicine and Chroma Medicine. When both firms double down on the same company, co-leading a nine-figure round, it signals deep conviction.
Tom Thomas from Newpath joined Create's board as part of the deal.
The proceeds will fund three specific priorities. First, Create plans to push its repeat-dose CD19-targeted in vivo CAR-T therapy for autoimmune disease into clinical trials. Second, it will expand a dual-targeting CD19 x BCMA program (BCMA is a protein commonly found on multiple myeloma cells). Third, it will continue advancing its broader oncology pipeline.
That repeat-dose capability deserves a closer look. Traditional CAR-T is essentially a one-shot deal; the engineered cells either work or they don't. Because Create's approach uses mRNA (which naturally degrades over time), CAR expression is temporary. That sounds like a weakness, but it's actually a feature: you can give patients multiple doses, adjusting as needed. Think of it as the difference between a permanent tattoo and a temporary one you can update.
A Crowded (and Exciting) Neighborhood
Create isn't the only company chasing in vivo CAR-T. The space has exploded, with more than 100 disclosed in vivo CAR assets expected by the end of 2025 and over $2 billion in aggregate funding flowing into the field.
Capstan Therapeutics is pursuing a similar LNP/mRNA approach. Umoja Biopharma uses a viral vector system called VivoVec and scored a high-profile alliance with AbbVie. Interius BioTherapeutics is building its own in vivo T-cell engineering platform. And big pharma is circling; AstraZeneca acquired EsoBiotec's program, while Sanofi, Moderna, and Legend Biotech are all exploring adjacent territory.
But clinical data separates dreamers from contenders. Create's 50-patient dataset is, for now, the biggest moat in the neighborhood. The question is whether that lead holds as competitors race into their own first-in-human trials.
The Bigger Picture
Approved CAR-T therapies (from Novartis, Gilead/Kite, BMS, and others) cost upwards of $400,000 per patient and require access to specialized treatment centers. That limits them to well-resourced hospitals in wealthy countries. Patients in rural areas, developing nations, or community oncology practices are largely shut out.
In vivo CAR-T could change that equation dramatically. If the therapy becomes a standardized infusion (think: IV bag, not personalized manufacturing facility), it could reach millions of patients who currently have no access. The cost compression potential alone is staggering.
Create's pipeline also hints at an even bigger opportunity: autoimmune disease. CAR-T therapies targeting CD19 have shown remarkable early results in conditions like lupus and systemic sclerosis, essentially rebooting the immune system by wiping out the B cells that drive disease. An in vivo version that patients could receive repeatedly, without the manufacturing hassle, could turn autoimmune treatment on its head.
What to Watch
Create Medicines has a compelling story: a proven delivery technology (mRNA + LNPs), a clinical head start (50-plus patients), heavyweight backers, and a massive addressable market spanning both cancer and autoimmune disease.
The challenges are real, though. Getting nanoparticles to reliably find T cells instead of accumulating in the liver remains technically difficult. Proving that transient CAR expression delivers durable clinical benefit will require larger, longer trials. And the competitive field is filling up fast.
But $122 million in fresh funding, from investors who already knew the company inside and out, suggests the early data is encouraging enough to keep building. In the race to make CAR-T therapy as simple as an infusion, Create just got a serious head start.
Clinical & Regulatory
5 min read
The 100% Tax That Could Break Big Pharma's Global Playbook
The Trump administration just slapped a 100% tariff on every branded drug not made in America, forcing pharma companies into an impossible choice: slash prices, build U.S. factories, or watch their margins evaporate. The biggest shake-up in pharma trade policy is already reshaping the industry.
